Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on July 2, 2014, regarding an event that occurred on July 1, 2014. The filing addresses corporate governance changes specifically related to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
The primary material change reported is the election of a new director:
- Appointment: Amy W. Schulman was elected as a Class III director by the Board of Directors.
- Term: Her term expires at the annual meeting of stockholders to be held in 2016.
- Compensation: Ms. Schulman received a stock option to purchase 30,000 shares of common stock, vesting annually over three years. She will also receive standard director compensation as outlined in the Company's 2014 Proxy Statement.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, financial guidance, risks, contingencies, or unusual items. The document is limited to the disclosure of the director election and associated compensatory arrangements.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 30,000 stock options granted to Amy W. Schulman.
- Review the Company's Proxy Statement for the 2014 Annual Meeting (filed April 29, 2014) to confirm the specific cash compensation policy for non-employee directors.
- Confirm the date of the 2016 annual meeting of stockholders to determine the exact expiration of the director's term.